As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.
The New Year is not yet three days old, but deal-hungry investors looking forward to next week’s JP Morgan conference already have a megamerger on their hands.
Allergan, Biogen, Bristol-Myers Squibb and Lilly follow Pfizer and Merck & Co on price increases, and there could be more to come at JP Morgan.
Vantage takes a look at the sellside’s naughty and nice list for 2018: prospects improved considerably for Merck & Co’s Keytruda and Abbvie’s Mavyret, the latter…
The struggling US biotech receives a $150m windfall from Gilead, a group desperate to make its mark in oncology.
Vantage publishes its annual look ahead to 2019, examining the trends and issues that will shape biopharma in the coming year.
A top three of early-stage CAR-T presentations from this year’s Ash meeting that you might have missed.
After years in the wilderness acute myeloid leukaemia is seeing a wave of activity, and there could be more targeted agents to come.
Ash presentations suggest that the lead asset Celgene acquired through its $9bn takeover of Juno is undergoing a shift of focus.